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Introduction: Melanocytes are cells which are present in the human skin and they 
are responsible for the melanin production. They can be found in the basal stratum of 
the epidermis and they have some prolongations extending until the stratum corneum. 
Melanin synthesis may increase in the presence of some factors and some irregular 
brownish spots – hyperpigmentations – may appear. Factors which can 
trigger melanogenesis are excessive sun exposure, hormonal contraception, 
hormonal reposition therapy, pregnancy, medicines, cosmetics, stress or genetics. 
Aim:  Understanding  of  the  relationship  between  hormonal  contraceptives  and 
hyperpigmentation. 
Material and Methods: A bibliographic  review through  a  research  in diverse 
databases (PubMed, Google Scholar, ScienceDirect and Wiley Online Library). 
Results/Discussion: According to some authors, estrogenic components found in 
hormonal contraceptives are associated with hyperpigmentation situations. In the case 
of progestagenic components, opinions diverge: some studies substantiate that 
progesterone has the ability to increase melanogenesis and others that it may have the 
opposite effect of estrogen. In a general way, most researchers say that hormonal 
contraceptives affect melanin synthesis; however others reject that fact. 
Conclusion: It is verified the relationship between hormonal contraceptives and 
hyperpigmentation. However, this topic is not sufficiently well approached, so future 
investigations are needed to allow its best understanding. 
 
 
Introduction 
Skin is the biggest multifunctional organ of the human body and it acts as a barrier against ultraviolet (UV) 
radiation, microorganisms’ invasions and chemical agents’ penetration. It also controls body fluids loss. The skin is 
an organ which is really important in thermoregulation and it also plays an important role in immunological, 
sensational and autonomous responses.(1) 
 
The skin is constituted by 3 main layers: the epidermis – the exterior layer, the dermis – the intermediate layer, and 
the hypodermis – the most interior and deep layer of the skin. In its turn, the epidermis is divided in 5 subdivisions: 
the stratum basale – most interior and deep, the stratum spinosum, the stratum granulosum, the stratum lucidum and 
the stratum corneum – the most exterior. The physic barrier is located mainly in the stratum corneum because on 
that stratum there are dead cells – keratinocytes -, nucleated epidermal cells and complexes formatted by keratin and 
proteins, evolved by a lipid matrix.(2) 
 
Melanocytes are the cells responsible for the production of melanin. They have an important function in skin 
protection against the malign effects of UV radiation. They are located in the stratum basale of the epidermis and 
they possess extensions until the stratum corneum, where the keratinocytes are. Melanocytes descend from precursor 
cells – melanoblasts. Melanocytes are responsible for skin tone, which differs from individual to individual 
according to its density, number, size and dispersion. Within the melanocytes, melanin is produced by 
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melanossomes – particles disposed in the cytoplasm of melanocytes, in which melanin is produced. After the 
production of melanin, it is transferred to the keratinocytes through the melanocytes’ extensions, where it is 
stored.(3,4) 
 
The melanin production happens inside the melanocyte through a process which requires the knowledge of basic 
physiology of the human cell as the structural and functional unit of all living beings: 
 
Tyrosinase is the bottom line for all the mechanism which leads to melanin production. It is an enzymatic complex 
synthetized in ribosomes and it is transferred to the Golgi complex. In the presence of oxygen, tyrosinase oxidizes 
tyrosine (an essential aminoacid) into dihydroxyphenylalanine (DOPA) and then DOPA into dopaquinone. From 
this point, the process can take two distinct pathways, depending on the presence or absence of cysteine. 
 
In the absence of cysteine (non-essential aminoacid), dopaquinone is converted into cyclodopa and then cyclodopa 
into dopachrome. Dopachrome is degraded by dopachrome tautomerase into dihydroxyindole (DHI), in greater 
proportion, and into dihydroxyindole-2-carboxylic acid (DHICA), in minor. Tyrosinase then oxidizes DHICA into 
eumelanin. 
 
In the presence of cysteine, dopaquinone reacts with it and forms cysteynildopa, which is oxidized into 
benzothiazinic intermediates, which produce pheomelanin. This process goes on while cysteine is present. When it 
finishes, it starts the process of production of eumelanin.(3,5) 
 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
Melanin production process (L-DOPA – L-3,4-dihydroxyphenylalanine; Trp-2 –tyrosinase-related protein-2; Trp-1 – 
tyrosinase-related protein-1; DHICA – dihydroxyindole-2-carboxylic acid; DHI – dihydroxyindole) Source: Uyen et al, 
2005 
 
Individual with a darker skin have a bigger production of eumelanin (darker pigment); those with a lighter skin have 
a bigger production of pheomelanin (lighter pigment). Eumelanin diffuses UV radiation, attenuates its penetration 
on skin and reduces its harmful effects, so people with darker skins can get tanner without getting burned. 
Pheomelanin generates free radicals in response to UV radiation and it is capable of causing damage in 
deoxyribonucleic acid (DNA), so people with lighter skins present higher risk of epidermal damage induced by UV 
radiation. Skin and hair colour result from the mixture of both melanins.(3,4) 
 
As a response to diverse stimulus, melanin synthesis may increase so there may appear some irregular brownish 
marks, especially in the areas exposed to sun radiation. Those areas are called hyperpigmented areas. Two common 
problems are melasma and post-inflammatory hyperpigmentation. The most prevalent situation is melasma, which is 
characterized by marks which appear on the face. Within other pathologies that consist on hyperpigmentations, there 
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can be found the following: periorbital hyperpigmentation, Riehl’s melanosis, exogenous ochronosis, dermatosis 
papulosa nigra, lentigo, lichen planus pigmentosus and freckles.(6,7) 
 
The most affected areas ate the forehead, the temples and the cheeks. This phenomenon affects mainly women on 
fertile age. Meanwhile, it can also affect men, although they represent 10% of all cases. The appearance of these 
cutaneous manifestations happens due to excessive sun exposure, hormonal contraception, hormonal reposition 
therapy, pregnancy, medicines, cosmetics or stress, and there is also a genetic component associated with this 
outcoming, with a probability around 40-60%.(3,8-12) 
  
Among the medicines that can cause hyperpigmentation there are antimalarial, amiodarone, cytotoxic, minocycline, 
chlorpromazine, tricyclic antidepressives and anticonvulsants. Hyperpigmentation develops slowly. The first marks 
and visible only months or even years after the taking.(11) 
 
The responsible genes for human pigmentation differ from population to population and inside the population, 
resulting on a different production of melanin and, consequently, on a bigger or smaller manifestation of cutaneous 
hyperpigmentations.(13) 
 
Deep down, melanin confers some protection to the skin because of its ability to absorb UV radiation and it also has 
antioxidant properties once it eliminates free radicals. Besides UV radiation, nowadays it is known that visible 
spectrum light may also have potential to cause hyperpigmentations, at least on the individuals with darker skin. (14,15) 
In the case of hormonal contraception, it is used for about 60% of women with ages between 16 and 30 years old. At 
first, contraceptives contained only progesterone; however, as time went by, there were seen a few undesirable 
androgenic effects, so it was introduced estrogen to the contraceptives. Nowadays, combined hormonal 
contraceptives are a very effective method of undesirable pregnancy prevention when used properly.(12,16) 
 
There are some hormonal contraceptive methods like oral contraception, vaginal ring, transdermal patch, intra 
uterine device, subcutaneous implant and injectable contraceptive. It is estimated that around 10 to 20% of women 
who use contraceptives develop this kind of marks. There are several studies about the area and it appears that the 
cause of this cutaneous expressions derives from the fact that most contraceptives contain estrogen in its 
composition. There are two types of estrogenic receptors which measure the biologic responses of estrogen in the 
human body. One of its responses may be the increase of melanogenesis.(12,16-18) 
 
So, the problem to approach is the possibility that the hormones contained in the hormonal contraceptives may be or 
may not be a potential cause of hyperpigmentations. 
 
Materials and methods 
This study is a bibliographic review, effectuated between September 2017 and May 2018. For this research, there 
were analysed free-access articles retrieved from online databases (PubMed, Google Scholar, ScienceDirect and 
Wiley Online Library), with the support of software and computer equipment. The articles had language restriction 
for Portuguese, English, Spanish and Polish and the keywords searched were “hormonal contraceptives”, 
“hyperpigmentation”, “estrogen”, “progesterone”, “melanin” and “pigmentation”. 
 
Inclusion criteria to use the articles found were: 
 
-Study of the relationship between the use of hormonal contraceptives and the emergence and/or aggravation of 
hyperpigmentation situations; 
 
-Date of publication in the last 10 years (2008-2017). 
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Results and discussion 
Given the theme under study, the research focused on bibliographical sources which debate the hypothesis that 
steroid hormones contained in the hormonal contraceptives constitute a potential to emerge and/or aggravate 
hyperpigmentations. Therefore, the presented review is focused on the demystification of that conjecture. 
 
1. Estrogenic components 
Sun et al., in 2017, determined through an in vitro study that estrogen promotes melanogenesis both in the skin and 
in the hair. This study allowed to conclude that women who take oral contraceptives which contain estrogen are 
more disposed to the development of cutaneous hyperpigmentations. It was discovered that UV radiation increases 
the proliferation of melanocytes, so it is a factor which upholds the effect of estrogen.(19) 
 
According to Tamega et al., estradiol present in the hormonal contraceptives causes, in a dose-dependent way, the 
increase of the activity of tyrosinase and dopachrome tautomerase, with the subsequent decrease of the proliferation 
of the melanocytes. This study in vitro was carried in the year of 2015, using samples of healthy cutaneous tissue 
and tissue affected by hyperpigmentations. The authors discovered that estradiol increases ribonucleic acid (RNA) 
levels of the melanocortin receptors type 1 (MCR-1), which is evolved in the regulation of melanin synthesis. The 
increase of MCR-1 expression is responsible for a higher activity of the keratinocytes, leading to a bigger production 
of melanin. These authors try to approach the way progesterone acts by the level of melanogenesis; however, the 
research is inconclusive so they appeal to the need of more studies.(20) 
 
Following Cohen, in 2017, estrogenic receptors - α and β - are both over-expressed in a hyperpigmented skin when 
compared to a normal skin. This fact happens due to the presence of high levels of estrogen. Estrogen, as referred 
by other authors, increases melanogenesis through stimulation of some proteins: tyrosinase, tyrosinase-related 
protein-1 (TRP-1), tyrosinase-related protein-2 (TRP-2) and melanogenesis associated transcription factor (MITF). 
On a microscopic exam performed on a hyperpigmented skin, it was possible to verify that the melanocytes were 
bigger and more prominent; yet, there weren’t more than before. Meanwhile, Asian women with 
hyperpigmentations in the face were evaluated as its lesions showed that melanin was more dispersed for all the 
epidermis but also a numeric increase of melanocytes, melanin and melanossomes.(21) 
 
As studied by Kim et al. in 2012, estrogen may induce the expression of PDZ domain containing 1 (PDZK1). This 
protein is clinically related to melasma. In this study there were used monocultures and co-cultures of melanocytes 
and keratinocytes with and without over-expression of PDZK1 form 15 individuals. The administered estrogen 
caused an increase of PDZK1 expression. This protein increases tyrosinase’s activity and the transfer of melanin 
from melanossomes to keratinocytes. PDZK1 inhibition reduced tyrosinase’s expression through regulation of the 
activity of α and β estrogen receptors. The authors also verified that hyperpigmented cells had a higher expression 
of PDZK1 in comparison to normal cells.(22) 
 
According to Lee, on a systematic review from 2015, melanogenesis induction by estrogen may occur through 
PDZK1 expression and may be associated to cyclic adenosine monophosphate (cAMP) cascade activation, once 
estrogen increases cAMP levels and the expression of tyrosinase and MITF.(23) 
 
Mahmood et al., on their research from year 2011, quote some studies in vitro which prove that melanocytes 
express estrogenic receptors and that estrogen increases levels of tyrosinase, TRP-1 and TRP-2 (Figure 2). The 
connection of melanocytes stimulation hormone (MSH) to MCR-1 receptors mediates melanogenesis which occur 
naturally in the human being. In the presence of estrogen, the expression of MCR-1 and tyrosinase increase, leading 
to an augmented melanogenesis.(24) 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanism evolved on melanogenesis induced by estrogen (ER – estrogen receptor; PDZK1 – PDZ domain containing 1; 
NHE3 – sodium-hydrogen antiporter 3; CFTR - Cystic fibrosis transmembrane conductance regulator; TYR - tyrosinase; 
TRP1 – tyrosinase-related protein-1; TRP1 – tyrosinase-related protein-2; MITF – melanogenesis associated transcription 
factor) 
Source: Lee, 2015 
 
In short: All the previously quoted authors associate estrogenic components in hormonal contraceptives with 
hyperpigmentation situations. Sun et al. also allege that UV radiation is an aggravating factor. Tamega et al. and 
Mahmood et al. studied the evolvement of MCR-1 receptors in melanogenesis. PDZK1 is over-expressed in 
hyperpigmented cells, as described for Lee and Kim et al. The implication of TRP-1 and TRP-2 is also evident, as 
studied for Cohen. 
 
2. Estrogenic and progestagenic components 
A cross-sectional study accomplished by Damayanti et al. in 2017, with a sample of 17 female individuals, allowed 
to associate the continuous use of oral combined contraceptives with the appearance of hyperpigmentations. They 
have concluded that women who took those contraceptives for at least 2 years have suffered the adverse effect on 
approach: hyperpigmentations. The authors determine that a period of three months of oral combined contraceptives 
may be enough to start mechanisms which can lead to hyperpigmentation.(25) 
 
A review study done by Gardini et al. in the year of 2011 allowed to associate the progression of a 
hyperpigmentation situation to an oncological situation of melanoma. The authors close the article concluding that 
the use oral contraceptives only containing estrogen or containing a combination of estrogen and progesterone 
increase melanin production and the number of melanocytes. However, those don’t increase the risk for developing 
melanoma.(26) 
 
Following Wiedemann et al., on a study in vitro on melanocytes in 2009, estrogen and progesterone caused its 
multiplication and increased tyrosinase’ activity on three from eight cell cultures. Still, when they studied the effects 
of progesterone isolated, there wasn’t any increase of tyrosinase but there was a decrease of the amount of melanin. 
Therefore, the authors conclude that progesterone present in hormonal contraceptives may have an inhibitory effect 
on the proliferation of melanocytes.(12) 
 
An in vitro study realized in 2016 allowed to Natale et al. to associate ethinylestradiol which is present in hormonal 
contraceptives with melanin production. The process that occurs naturally to form melanin is regulated by MSH. As 
referred by other authors, MSH links to MCR-1, activating adenylcyclase and increasing cAMP. This molecule 
triggers a cascade of events required to melanin synthesis. Women who use hormonal contraceptives keep this 
process dependent of MSH. Nevertheless, after in vitro evaluation of the behaviour of melanocytes which had been 
Open Access Journal                                                                                                                                 
 
International Journal of Medical Research and Pharmaceutical Sciences 
Volume 6 (Issue 3): March 2019                                                                                    ISSN: 2394-9414 
DOI- 10.5281/zenodo.2616927                                                                              Impact Factor- 4.174 
©International Journal of Medical Research and Pharmaceutical Sciences http://www.ijmprsjournal.com/ 
 
 
17 
treated with estrogen, melanin synthesis increased in about 208%, without affecting the number or density of 
melanocytes. The authors also evaluate the production of melanin when progesterone was administered. They 
concluded that progesterone has the opposite effect of estrogen, diminishing melanin production in about 58%. So, 
the conclusion of this study leaves the possibility that, in the case of use of hormonal combined contraceptives, the 
stimulatory effects of estrogen can be antagonized by the presence of progesterone.(27) 
 
According to Hyun Jang et al., in 2012, estrogen and progesterone are related to hyperpigmentation. Estrogen 
interacts and activates α and β estrogenic receptors. The expression of β-estrogenic receptor is predominant in case 
of lesion of melanocytes. This discover suggests that estrogen and its analogues, by interacting with this receptor, 
play an important role on physiology and physiopathology of the melanocyte. As for progesterone, the researchers 
assume that it stimulates melanogenesis in the melanocytes, although they say that its function, as said for other 
studies, inhibits melanogenesis.(28) 
 
An in vitro study conducted by Jang et al. in 2010 consisted in comparing the expression of estrogenic and 
progestagenic receptors between hyperpigmented areas and non-affected areas from the faces of individuals with 
melasma. All the participants were female and had been suffering from the problem for at least 8 years. Although 
the protective effects of estrogen against skin aging, the authors allege that estrogen increases melanin activity, 
inducing skin pigmentation. Between the two estrogen receptors already mentioned, the β-estrogenic receptor is the 
predominant one on the lesions of melanocytes. Results indicate a higher activity of those receptors in skins affected 
by melasma on the epidermis, essentially on stratum basale and stratum spinosum, on which β-estrogenic receptors 
present a greater immunoreactivity than those on stratum granulosum. There wasn’t found any specific expression of 
receptors in affected skin, neither in the surrounding healthy tissues. As for progesterone receptors, its expression 
was also higher in skin with lesions. Therefore, investigators prove that the melanin amount present in skin affected 
by melasma was superior in comparison to non-affected skin and they associate positively hormonal receptors like 
estrogenic and progestagenic with skin lesions derived from melasma.(29) 
 
In short: Through the analysis of precious data, it is understandable that according to Damayanti et al., Gardini et 
al., Hyun Jang et al. and Jang et al. estrogen and progesterone both possess ability to increase melanogenesis. 
However, Wiedemann et al. and Natale et al. say that only estrogen presents stimulatory effects of melanogenesis 
and that progesterone could have the opposite effect of estrogen. 
 
3. Unknown components 
In 2015, Pietrzak et al. observed that long term use of hormonal contraceptives increases the amount of 
melanossomes in melanocytes, increases its metabolism and, as a consequence, increases melanin production. The 
authors suggest that exposure to UV radiation may rise the risk of development of hyperpigmentations.(30) 
 
As studied by Krupashankar & Somani in the year of 2014, with the aim of evaluating the epidemiology of melasma 
associated with diverse factors (including oral contraceptive use), 266 women with melasma were evaluated, from 
which only 23 (8,6%) had taken oral contraceptives. 7 of them took it for 1 to 3 years. This way, the authors 
conclude that there is no statistically significant relationship; meanwhile, they appeal to the need for more studies 
around the subject.(31) 
A case-control study performed in women in 2009 by Applebaum et al. allowed to make an association between oral 
contraceptive use and the prevalence of squamous cell carcinoma (SCC). In this study, the authors recognize that 
oral contraceptive taking changes cell response to exposure to UV radiation, making it more susceptible to its 
effects. From 261 cases and 298 controls, only 7 cases and 4 controls had experienced melasma and the duration of 
oral contraceptive use was equal in women who had not had that experience. In other words, from women who took 
oral contraceptives for the same time, only a few developed hyperpigmentations. This fact lead the investigators to 
conclude that hormonal contraceptive use is not statistically related to hyperpigmentation.(32) 
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In a case-control study 312 individuals with hyperpigmentation in the face were evaluated, in the year of 2011. 250 
individuals were female and 62 were male. From all women included in the study, only 18,4% took oral 
contraceptives during the follow-up period. Results show that there is no significant relationship between taking oral 
contraceptives and the appearance or aggravation of hyperpigmentation. However, this study only had a follow-up 
period of one year (January 2009 to December 2009), so the effects of estrogen may not have been perceptible 
within this range.(33) 
 
According to an observational study of Guinot et al. from year 2010, with a sample of 197 individuals, from which 
188 were female, oral contraceptives are effectively a factor which interferes with the appearance of 
hyperpigmentations in the face. 135 women had never used oral contraceptives, 40 had used but discontinued its use 
and the other 13 were still taking it. The authors conclude that oral contraceptives constitute a triggering factor in 
26% of all cases and aggravating factor in 38%. Yet, the severity level of lesions varies according to ethnic group. 
Melasma arises 1 to 3 years after the first taking and disappears slower than marks triggered by pregnancy (some 
marks never disappear totally). In this study, the investigators say that melasma represents about two thirds of all 
cutaneous secondary effects of oral contraceptives.(34) 
 
In short: Most studies in this category reject the hypothesis that hormonal contraceptives implicate 
hyperpigmentation situations, as described by Krupashankar & Somani, Applebaum et al. and Rathi & Achar. On 
other hand, Pietrzak et al. and Guinot et al. found a relationship between hormonal contraceptives use and the 
appearance and/or aggravation of hyperpigmentations. One aspect to point in these studies conducted by 
Krupashankar & Somani and Rathi & Achar is the low number of women who took hormonal contraceptives in 
comparison to the total of women in the sample. 
 
Conclusion 
After the present research, it is concluded that hormonal contraceptives use is related to the appearance and/or 
aggravation of hyperpigmentation situations. 
 
Although some authors conclude that estrogen present in hormonal contraceptives doesn’t have a statistically 
significant relationship with the object of study, most studies substantiate that there is a cause-effect relationship. 
The role of progesterone is not yet entirely clarified, once there are some studies which point its synergic potential 
with estrogen while others mention its antagonist and protective action from the cutaneous effects of estrogen. 
About the population studies, it is important to remark that tiny samples and/or restricted follow-up periods will not 
allow the obtaining of reliable results. 
 
Another limit on the found studies was the fact that the main problem of hyperpigmentation is melasma. As for the 
remaining pathologies associated to hyperpigmentations, the information is quite reduced. 
 
Therefore, it is verified the positive association between hormonal contraceptive use and hyperpigmentation. 
However, the achievement of profitable articles for this study was an arduous task because the existing studies are 
still rare. It becomes necessary to deepen studies about the role of progesterone and other diseases caused by 
hyperpigmentations. The relationship between hormonal contraceptives and hyperpigmentation is a subject which 
needs future investigations so that it can be fully demystified. 
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